The biotech and medtech entrepreneur Philippe Dro has joined Scenic Biotech BV of the Netherlands as independent chairman of the board of directors. Dr Dro’s most recent experience has been in the vaccine sector where he was board member and chief business officer at Themis Biosciences through to its sale to Merck & Co Inc. He was also chief executive and supervisory board member at GlycoVaxyn, now part of GlaxoSmithKline Plc. He joins Scenic Biotech as the company identifies genetic modifiers, a new class of disease targets for drug intervention.
Scenic Biotech announced the appointment on 2 February 2021
Copyright 2021 Evernow Publishing Ltd.